Zacks Investment Research lowered shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a buy rating to a hold rating in a report released on Thursday morning.
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
BCRX has been the topic of a number of other research reports. Needham & Company LLC reiterated a hold rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 12th. BidaskClub upgraded BioCryst Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, August 1st. HC Wainwright reiterated a buy rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. Noble Financial reiterated a buy rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. Finally, ValuEngine downgraded BioCryst Pharmaceuticals from a hold rating to a sell rating in a report on Thursday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $8.00.
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 5.10% during midday trading on Thursday, reaching $4.53. The company’s stock had a trading volume of 824,839 shares. The stock’s market cap is $364.34 million. BioCryst Pharmaceuticals has a 52-week low of $3.75 and a 52-week high of $9.25. The stock has a 50-day moving average price of $5.36 and a 200-day moving average price of $6.28.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $5.79 million. During the same quarter last year, the company posted ($0.22) EPS. The firm’s revenue was down 35.4% on a year-over-year basis. Equities research analysts anticipate that BioCryst Pharmaceuticals will post ($0.72) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://transcriptdaily.com/2017/08/13/biocryst-pharmaceuticals-inc-nasdaqbcrx-downgraded-by-zacks-investment-research.html.
Several hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares during the last quarter. ProShare Advisors LLC increased its stake in BioCryst Pharmaceuticals by 0.9% in the second quarter. ProShare Advisors LLC now owns 48,354 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 427 shares during the last quarter. Legal & General Group Plc increased its stake in BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 860 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,500 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in BioCryst Pharmaceuticals by 4.5% in the second quarter. Nationwide Fund Advisors now owns 46,149 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 1,975 shares during the last quarter. Institutional investors own 84.49% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.